Arena Pharmaceuticals, Inc. (ARNA) News

Arena Pharmaceuticals, Inc. (ARNA)

Today's Latest Price: $63.59 USD

1.74 (-2.66%)

Updated Aug 14 12:00am

Add ARNA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

Filter ARNA News Items

ARNA News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest ARNA News From Around the Web

Below are the latest news stories about Arena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARNA as an investment opportunity.

Arena Pharmaceuticals to Release Second Quarter 2020 Financial Results and Provide Corporate Update on August 5

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2020 financial results and provide a corporate update on Wednesday, August 5, 2020, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live webcast with the investment community the same day at 4:30 PM ET.

Yahoo | July 29, 2020

Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on July 15, 2020, the Compensation Committee of its Board of Directors granted to six new employees inducement stock options to purchase an aggregate of 35,850 shares of its common stock and 6,310 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of July 15, 2020, and were granted as inducements material to the new employees entering into employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).

Yahoo | July 17, 2020

What Kind Of Shareholders Own Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?

If you want to know who really controls Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), then you'll have to look at the...

Yahoo | July 13, 2020

Did Hedge Funds Make The Right Call On Arena Pharmaceuticals, Inc. (ARNA) ?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 12, 2020

Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors

SAN DIEGO, June 15, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Dr. Katharine Knobil to the Company's Board of Directors. Dr. Knobil brings more than 20 years of leadership and expertise across a range of areas including global…

PR Newswire | June 15, 2020

Arena Pharmaceuticals Announces R&D Leadership Transition

SAN DIEGO, June 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to its research and development leadership team. Effective June 9, 2020, Dr. Preston Klassen will be leaving the Company to pursue an opportunity as Chief Executive Officer of a San…

PR Newswire | June 8, 2020

Edited Transcript of ARNA earnings conference call or presentation 7-May-20 8:30pm GMT

Q1 2020 Arena Pharmaceuticals Inc Earnings Call

Yahoo | June 8, 2020

Hedge Funds Aren’t Done Buying Arena Pharmaceuticals, Inc. (ARNA)

In this article we will check out the progression of hedge fund sentiment towards Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

Yahoo | June 3, 2020

Cannabis Stock Gainers And Losers From June 2, 2020

Gainers: Arena Pharmaceuticals (NASDAQ: ARNA ) shares closed up 16.22% at $68.22 Alcanna (OTC: LQSIF ) shares closed up 15.05% at $2.36 Australis Capital (OTC: AUSAF ) shares closed up 8.93% at $0.20 Halo Labs (OTC: AGEEF ) shares closed up 8.23% at $0.08 GrowGeneration (NASDAQ: Full story available on

Benzinga Feeds | June 2, 2020

Why Bristol Myers' Success In Ulcerative Colitis Sent Arena Stock Flying

Bristol Myers Squibb reported positive ulcerative colitis treatment data Tuesday helping shares of rival Arena Pharmaceuticals to pop. Arena is testing a similar drug called etrasimod.

Yahoo | June 2, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6216 seconds.